LEADING
WITH INNOVATION
We're entering 2025 with momentum and strength. As the long-standing leader in HIV, we’re committed to helping end the epidemic with the advancement of unprecedented long-acting medications for both HIV prevention and treatment. Our diversified pipeline has the potential to deliver best-in-class therapies to address multiple myeloma and other types of cancer, the rare liver disease primary biliary cholangitis, and other diseases across our therapeutic areas.
Delivering Transformative Therapies and Advancing Health Equity
Through innovation, we’re helping to build a healthier world for all people.
Learn More About GileadMedicines Offered Globally
Clinical Programs Across Virology, Oncology and Inflammation
Funder of HIV Programs in the U.S.
Using Science to Improve the Lives of People and Communities
We invest in world-class science to combat the world's most devastating diseases.
Explore ScienceA Strong Pipeline Spanning Three Therapeutic Areas
We have a deep, diverse pipeline across Virology, Oncology and Inflammation.
View Our PipelineAn Inclusive Workplace Where We All Can Make an Impact
More than 18,000 employees at Gilead worldwide work to advance scientific innovation, help ensure our medicines reach those who need it and make a difference in the communities where we live and work.
Explore Careers at GileadNews
Some of the content on this page is not intended for users outside the U.S.
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
March 12, 2025First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
March 11, 2025European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention
February 24, 2025Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
February 20, 2025Gilead Sciences to Present at Upcoming Investor Conferences
February 19, 2025U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
February 18, 2025
Investors